COMP <GO>
NUTX vs LQDT // EV/EBITDA & P/E VALUATION
Nutex Health Inc. (NASDAQ) VS. Liquidity Services Inc. (NASDAQ) • 15-METRIC TALLY: NUTX 10
— LQDT 2
▲ EV/EBITDA & P/E VALUATION LEADER: NUTX
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
valuation
4.6x
LAST: $45.29 (+3.32%) • MKT CAP: $1.42B
valuation
34.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUTX VS. LQDT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUTX | LQDT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.80% | 43.80% | +7.00 | NUTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 12.90% | +72.10 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 4.6x | 34.0x | -29.40 | NUTX | /valuation <GO> |
| Free Cash Flow Yield | 17.07% | 4.15% | +12.92 | NUTX | /fcf-yield <GO> |
| Operating Margin | 31.50% | 7.40% | +24.10 | NUTX | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 5.90% | +2.20 | NUTX | /net-margins <GO> |
| Revenue Growth (YoY) | 82.40% | 31.20% | +51.20 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.75 | 7.56 | -3.81 | LQDT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 55.8 | -9.16 | LQDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.1x | 42.4x | -25.30 | NUTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $1.42B | $19.8M | NUTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUTX REV | LQDT REV | NUTX GROSS % | LQDT GROSS % | NUTX FCF | LQDT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $875.3M | $476.7M | 50.8% | 43.8% | $245.6M | $59.0M |
| FY 2024 | $479.9M | $363.3M | 40.9% | 51.0% | $20.8M | $61.3M |
| FY 2023 | $247.6M | $314.5M | — | — | $1.3M | $47.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUTX // BETA —
LQDT // BETA —